Skip to main content

Peer Review reports

From: Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis

Original Submission
27 Feb 2020 Submitted Original manuscript
19 Mar 2020 Reviewed Reviewer Report - Kerstin Klein
17 Aug 2020 Reviewed Reviewer Report - Scott E. Wenderfer
9 Oct 2020 Author responded Author comments - Christopher W. Pohlmeyer
Resubmission - Version 2
9 Oct 2020 Submitted Manuscript version 2
31 Oct 2020 Reviewed Reviewer Report - Scott E. Wenderfer
28 Dec 2020 Author responded Author comments - Christopher W. Pohlmeyer
Resubmission - Version 3
28 Dec 2020 Submitted Manuscript version 3
18 Jan 2021 Author responded Author comments - Christopher W. Pohlmeyer
Resubmission - Version 4
18 Jan 2021 Submitted Manuscript version 4
Publishing
22 Jan 2021 Editorially accepted
30 Mar 2021 Article published 10.1186/s41927-021-00178-3

You can find further information about peer review here.

Back to article page